How the concept of WHO-listed authorities will change international procurement policies for medicines.
作者信息
Macé Cécile, Rägo Lembit, Ravinetto Raffaella
机构信息
Independent Consultant, Nantes, France.
Secretary-General, Council for International Organisations of Medical Sciences, Geneva, Switzerland.
出版信息
BMJ Glob Health. 2022 Feb;6(Suppl 3). doi: 10.1136/bmjgh-2021-008109.
Abstract
摘要
相似文献
1
How the concept of WHO-listed authorities will change international procurement policies for medicines.
BMJ Glob Health. 2022 Feb;6(Suppl 3). doi: 10.1136/bmjgh-2021-008109.
2
[Counterfeit medicines--Japan and the world].
Yakugaku Zasshi. 2014;134(2):213-22. doi: 10.1248/yakushi.13-00230-3.
3
Drug and alcohol policy at the global level.
Drug Alcohol Rev. 2006 Nov;25(6):485-7. doi: 10.1080/09595230600944438.
4
Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy.
J Pain Palliat Care Pharmacother. 2011;25(3):246-51. doi: 10.3109/15360288.2011.599485.
5
Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
BMC Public Health. 2014 Jul 30;14:767. doi: 10.1186/1471-2458-14-767.
6
The new European Union drugs strategy 2013-2020: a different outlook to managing drug dependence.
Addiction. 2013 Jul;108(7):1349-50. doi: 10.1111/add.12198. Epub 2013 Apr 25.
7
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(8):867-878. doi: 10.1080/14737167.2023.2237683. Epub 2023 Jul 26.
8
Rational use of medicines, pharmaceuticalization and uses of methylphenidate.
Cien Saude Colet. 2017 Aug;22(8):2571-2580. doi: 10.1590/1413-81232017228.08622017.
9
Towards medicines regulatory authorities' quality performance improvement: value for public health.
Int J Health Plann Manage. 2016 Jan-Mar;31(1):E22-40. doi: 10.1002/hpm.2265. Epub 2014 Jul 2.
10
National medicines policy development, Saudi Arabia.
Bull World Health Organ. 2022 Aug 1;100(8):511-519. doi: 10.2471/BLT.22.287936. Epub 2022 Jun 22.
引用本文的文献
1
Understanding the regulatory-procurement interface for medicines in Africa via publicly available information on standards, implementation, and enforcement in five countries.
J Pharm Policy Pract. 2025 Jan 9;18(1):2436898. doi: 10.1080/20523211.2024.2436898. eCollection 2025.
2
Vaccines for neglected tropical diseases: Learnings from COVID-19.
Indian J Med Res. 2024;160(3&4):319-322. doi: 10.25259/IJMR_1548_2024.
3
Relationship between Prices and Quality of Essential Medicines from Different Manufacturers Collected in Cameroon, the Democratic Republic of the Congo, and Nigeria.
Am J Trop Med Hyg. 2024 Oct 8;111(6):1378-1395. doi: 10.4269/ajtmh.24-0309. Print 2024 Dec 4.
4
WHO-listed authorities (WLA) framework: transparent evidence-based approach for promoting regulatory reliance towards increased access to quality-assured medical products.
Front Med (Lausanne). 2024 Sep 23;11:1467229. doi: 10.3389/fmed.2024.1467229. eCollection 2024.
5
Identifying and costing common gaps in Central and West Africa pharmaceutical regulation.
Front Med (Lausanne). 2024 Apr 5;11:1362253. doi: 10.3389/fmed.2024.1362253. eCollection 2024.
6
Report for the Eighth Asian National Control Laboratory Network meeting in 2023: Self-sufficiency strategy of plasma-derived medicinal products and regulatory harmonisation.
Biologicals. 2024 Feb;85:101754. doi: 10.1016/j.biologicals.2024.101754. Epub 2024 Mar 1.
7
Shaping the future of global access to safe, effective, appropriate and quality health products.
BMJ Glob Health. 2024 Jan 9;9(1):e014425. doi: 10.1136/bmjgh-2023-014425.
8
Challenges of Antibiotic Formulations and Administration in the Treatment of Bloodstream Infections in Children Under Five Admitted to Kisantu Hospital, Democratic Republic of Congo.
Am J Trop Med Hyg. 2023 Oct 30;109(6):1245-1259. doi: 10.4269/ajtmh.23-0322. Print 2023 Dec 6.
9
The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities.
J Pharm Policy Pract. 2023 Oct 6;16(1):117. doi: 10.1186/s40545-023-00628-y.
10
Strengthening regulatory systems globally: a crucial step towards pandemic preparedness and response.
BMJ Glob Health. 2023 Aug;8(8). doi: 10.1136/bmjgh-2023-012883.
本文引用的文献
1
The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage.
Front Med (Lausanne). 2020 Aug 19;7:457. doi: 10.3389/fmed.2020.00457. eCollection 2020.
2
The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity.
BMJ Glob Health. 2020 Aug;5(8). doi: 10.1136/bmjgh-2020-003181.
3
Tackling the blind spot of poor-quality medicines in Universal Health Coverage.
J Pharm Policy Pract. 2020 May 11;13:40. doi: 10.1186/s40545-020-00208-4. eCollection 2020.
4
Importance of medicine quality in achieving universal health coverage.
PLoS One. 2020 Jul 9;15(7):e0232966. doi: 10.1371/journal.pone.0232966. eCollection 2020.
5
Global access to quality-assured medical products: the Oxford Statement and call to action.
Lancet Glob Health. 2019 Dec;7(12):e1609-e1611. doi: 10.1016/S2214-109X(19)30426-7.
6
Quality of medicines in resource-limited settings: need for ethical guidance.
Glob Bioeth. 2018 Sep 18;29(1):81-94. doi: 10.1080/11287462.2018.1522991. eCollection 2018.
7
Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy.
J Pharm Policy Pract. 2016 Nov 10;9:36. doi: 10.1186/s40545-016-0088-0. eCollection 2016.
Zotero 插件